Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: Spanish Breast Cancer Research Group
Collaborators: AstraZeneca